Silexion Therapeutics Ltd. (SLXNW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Silexion Therapeutics Ltd. (SLXNW) trades at $0.015. Silexion Therapeutics LTD is a biopharmaceutical company focused on developing RNA interference (RNAi)-based cancer drugs and delivery systems. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SLXNW: SLXNW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SLXNW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SLXNW: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Silexion Therapeutics Ltd. (SLXNW) Healthcare & Pipeline Overview
Silexion Therapeutics LTD, founded in 2008 and based in Jerusalem, is a biotechnology firm specializing in RNAi-based cancer therapies. Their LODER delivery platform aims to treat solid tumors, with ongoing pre-clinical and clinical trials. The company operates in a competitive biotech landscape with a focus on innovative drug delivery.
What Is the Investment Thesis for SLXNW?
Silexion Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's proprietary LODER platform offers a novel approach to targeted drug delivery, potentially improving the efficacy and safety of RNAi-based cancer therapies. The successful completion of pre-clinical studies and a Phase I clinical trial for SiG12D-LODER provides initial validation of the technology. Key value drivers include the advancement of its pipeline assets through clinical development, securing strategic partnerships, and demonstrating clinical efficacy in larger patient populations. The company's small size and limited financial resources pose significant risks, as does the inherent uncertainty of drug development. With a market capitalization of $0.00B and a negative P/E ratio of -0.24, the company's valuation is speculative and dependent on future clinical and regulatory milestones. The negative beta of -0.04 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
SLXNW Key Highlights
Proprietary LODER delivery platform for targeted RNAi-based cancer therapies.
- SiG12D-LODER has completed pre-clinical studies and a Phase I clinical trial for pancreatic cancer.
- Pipeline includes Prostate-LODER and GBM-LODER in pre-clinical development for prostate cancer and Glioblastoma Multiforme, respectively.
- Headquartered in Jerusalem, Israel, positioning the company within the Israeli biotech ecosystem.
- Small team of 11 employees focused on research and early-stage development.
Who Are SLXNW's Competitors?
SLXNW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKTX Akari Therapeutics, Plc | $7.79 | -1.39% | $8.92M | — |
| DRMA Dermata Therapeutics, Inc. | $1.38 | -6.12% | — | |
| PIII P3 Health Partners Inc. | $10.27 | -4.64% | $33.6M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SLXNW's Key Strengths?
Proprietary LODER delivery platform for targeted drug delivery.
- Focus on RNAi-based therapeutics, a promising area of cancer research.
- Pipeline of drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
What Are SLXNW's Weaknesses?
Limited financial resources and small team size.
- Early-stage development pipeline with significant clinical and regulatory risks.
- Dependence on partnerships for further development and commercialization.
- Lack of established revenue streams.
What Could Drive SLXNW Stock Higher?
SLXNW catalyst: Initiation of Phase II clinical trials for SiG12D-LODER in pancreatic cancer (timeline dependent on funding and regulatory approvals).
- Pre-clinical data release for Prostate-LODER and GBM-LODER (expected within the next 12-18 months).
- Potential for strategic partnerships with pharmaceutical companies for co-development or licensing agreements.
- Advancements in RNAi technology and drug delivery systems.
What Are the Key Risks for SLXNW?
Financial-distress signal — its Altman Z-Score of -24.71 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays in drug development.
- Regulatory hurdles and challenges in obtaining marketing approval.
- Competition from other biotechnology and pharmaceutical companies.
- Limited financial resources and dependence on external funding.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for SLXNW?
- Expansion of SiG12D-LODER clinical trials: Silexion has the opportunity to expand clinical trials for SiG12D-LODER beyond the initial Phase I study. Advancing to Phase II and Phase III trials, potentially in combination with other therapies, could demonstrate improved efficacy and lead to regulatory approval. Timeline: 2-5 years.
- Advancement of Prostate-LODER: Progressing Prostate-LODER through pre-clinical and clinical development represents a key growth opportunity. Prostate cancer is a prevalent disease, and new treatment options are needed, particularly for advanced or resistant cases. Successful development of Prostate-LODER could capture a share of the multi-billion dollar prostate cancer therapy market. Timeline: 3-7 years.
- Development of GBM-LODER: Silexion's GBM-LODER targets Glioblastoma Multiforme, an aggressive brain tumor with limited treatment options. Successful pre-clinical and clinical development could address a significant unmet medical need and capture a portion of the GBM therapy market. The market for GBM therapies is expected to grow as new diagnostic and treatment approaches emerge. Timeline: 4-8 years.
- Strategic Partnerships: Silexion can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its LODER-based therapies. Collaborations could provide access to funding, expertise, and distribution networks. Partnering with companies specializing in oncology or drug delivery could enhance Silexion's capabilities and market reach. Timeline: Ongoing.
- Expansion to New Cancer Targets: The LODER platform has the potential to be applied to other cancer types beyond pancreatic, prostate, and brain cancer. Identifying and validating new RNAi targets for other solid tumors could expand Silexion's pipeline and address a broader range of unmet medical needs. This could involve research collaborations or internal discovery efforts. Timeline: Ongoing.
What Are SLXNW's Competitive Advantages?
- Proprietary LODER delivery platform.
- Patent protection for RNAi-based drug candidates.
- Expertise in RNA interference technology.
- First-mover advantage in specific cancer targets.
What Does SLXNW Do?
Silexion Therapeutics LTD, established in 2008, is a biopharmaceutical company dedicated to the discovery and development of innovative cancer drugs and delivery systems based on RNA interference (RNAi) technology. Headquartered in Jerusalem, Israel, the company focuses on addressing the unmet needs in the treatment of malignant solid tumors. Silexion's core technology is its proprietary LODER (Local Drug EluteR) delivery platform, designed to provide sustained, local delivery of RNAi therapeutics directly to the tumor site. This targeted approach aims to maximize therapeutic efficacy while minimizing systemic side effects. The company's pipeline includes several product candidates in various stages of development. SiG12D-LODER, targeting the KRAS oncogene, has completed pre-clinical studies and an open-label Phase I clinical trial for the treatment of pancreatic cancer. Prostate-LODER is in pre-clinical development for prostate cancer, and GBM-LODER is in pre-clinical studies targeting Glioblastoma Multiforme (GBM), an aggressive primary brain tumor. Silexion's strategy involves advancing its LODER-based therapies through clinical trials and seeking partnerships for further development and commercialization. The company operates with a small team of 11 employees, reflecting its focus on research and early-stage development.
What Products and Services Does SLXNW Offer?
- Develops RNA interference (RNAi)-based cancer drugs.
- Creates delivery systems for targeted cancer therapies.
- Utilizes the proprietary LODER delivery platform.
- Focuses on treating malignant solid tumors.
- Conducts pre-clinical and clinical studies for drug candidates.
- Targets pancreatic, prostate, and brain cancers.
How Does SLXNW Make Money?
- Develops and patents RNAi-based cancer therapeutics.
- Out-licenses or partners with pharmaceutical companies for clinical development and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Focuses on early-stage drug discovery and development.
What Industry Does SLXNW Operate In?
Silexion Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for cancer therapies is substantial and growing, driven by an aging population and increasing incidence of cancer. RNAi-based therapeutics represent a promising area of innovation, offering the potential to target previously undruggable targets. Silexion's LODER platform aims to differentiate itself by providing a localized and sustained delivery of RNAi drugs, potentially improving efficacy and reducing side effects. The company competes with other biotechnology companies developing RNAi therapeutics and drug delivery systems.
Who Are SLXNW's Key Customers?
- Potentially pharmaceutical companies seeking novel cancer therapies.
- Future patients suffering from solid tumors (indirectly).
- Research institutions interested in RNAi technology.
Company Profile
Silexion Therapeutics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jerusalem, IL. The company is led by CEO Ilan Hadar. SLXNW has traded publicly since 2024.
Financial Health
Silexion Therapeutics Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.71 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Silexion Therapeutics Ltd. revenue of about $0 for fiscal 2026, with EPS near $-53.10.
Insider Activity
Over the past six months, Silexion Therapeutics Ltd. insiders filed 4 SEC Form 4 transactions — 1 sales and 3 purchases. On net that is roughly 682 shares acquired (about $31K) — insiders putting money in tends to read as conviction.
SLXNW Financials
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SLXNW Latest News
No recent news available for SLXNW.
SLXNW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SLXNW.
Price Targets
Wall Street price target analysis for SLXNW.
SLXNW MoonshotScore
What does this score mean?
The MoonshotScore rates SLXNW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ilan Hadar
CEO
Ilan Hadar serves as the CEO of Silexion Therapeutics LTD. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. Therefore, a comprehensive background profile cannot be generated at this time. His leadership is focused on guiding the company's strategic direction and overseeing the development of its RNAi-based cancer therapies.
Track Record: Due to the limited information available in the provided source data, it is not possible to provide a detailed track record of Ilan Hadar's achievements, strategic decisions, or company milestones under his leadership. His primary focus is currently on advancing Silexion's pipeline of drug candidates through pre-clinical and clinical development.
Common Questions About SLXNW (Healthcare)
What does Silexion Therapeutics Ltd. do?
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based cancer drugs and delivery systems. The company's core technology is its proprietary LODER (Local Drug EluteR) platform, which enables targeted and sustained delivery of RNAi therapeutics directly to solid tumors.
What do analysts say about SLXNW stock?
As of 2026-03-16, there is no available analyst coverage or consensus for SLXNW stock due to its early-stage nature and limited trading activity. The company's valuation is primarily based on its intellectual property, pipeline assets, and potential for future clinical and regulatory milestones.
What are the main risks for SLXNW?
Silexion Therapeutics faces several key risks inherent to the biotechnology industry. These include the risk of clinical trial failures, regulatory setbacks, competition from larger pharmaceutical companies, and the need for significant capital to fund ongoing research and development. The success of Silexion's LODER platform and its drug candidates depends on demonstrating clinical efficacy and safety in larger patient populations.
What are the key factors to evaluate for SLXNW?
Evaluate SLXNW on fundamentals, analyst consensus, and risk factors. Silexion Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. Not financial advice.
How frequently does SLXNW data refresh on this page?
SLXNW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SLXNW's recent stock price performance?
Silexion Therapeutics Ltd. (SLXNW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary LODER delivery platform for targeted drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SLXNW overvalued or undervalued right now?
Silexion Therapeutics Ltd. (SLXNW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SLXNW before investing?
Before investing in Silexion Therapeutics Ltd. (SLXNW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited source data.
- AI analysis is pending and may provide further insights.
- Valuation metrics may not be reliable due to the company's early stage.